FDA accepts Unicycive’s resubmitted kidney‑disease drug NDA, sets March 2027 PDUFA date
Unicycive Therapeutics announced that the FDA has accepted its resubmitted New Drug Application for oxylanthanum carbonate, an oral phosphate binder for patients on dialysis. The agency assigned a PDUFA target action date of March 25, 2027. The filing adds chemistry, manufacturing and controls data from a new third‑party producer, addressing deficiencies noted in a June 2026 Complete Response Letter. The company’s shares rose over 4% in pre‑market trading following the news.
Why it matters
The acceptance removes a regulatory hurdle and gives the drug a six‑month review window, which investors see as a catalyst; the stock gained roughly 4% in pre‑market trading after the announcement.
Key facts
- 1The FDA accepted the resubmission of Unicycive’s NDA for oxylanthanum carbonate. stocktitan.net
- 2The agency set a PDUFA target action date of March 25, 2027. stocktitan.net
- 3The resubmission contains chemistry, manufacturing and controls data from a new third‑party drug product vendor. stocktitan.net
- 4The new vendor’s facility was inspected by the FDA in March 2024 and received a “No Action Indicated” finding. stocktitan.net
- 5Unicycive received a Complete Response Letter in June 2026, prompting the resubmission. stocktitan.net
- 6UNCY shares rose about 4.2% in pre‑market trading after the FDA acceptance was announced. rttnews.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.